Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio clínico de un generador de impulsos microimplantable para el tratamiento del dolor neuropático periférico (COMFORT)

21 de octubre de 2026 actualizado por: Nalu Medical, Inc.

This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or post-surgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.

Descripción general del estudio

Descripción detallada

Multi-center, prospective, open-label, randomized controlled trial (RCT) comparing PNS plus CMM with CMM alone. Subjects will be randomized to receive:

Arm 1: Nalu Neurostimulation System for PNS plus CMM Arm 2: CMM alone Consented subjects will receive a baseline evaluation and then be randomized 2:1 into one of two arms: 1) PNS+CMM arm or 2) CMM arm. Subjects assigned to Arm 1 will undergo a trial implant period using best clinical practices. Those subjects who pass the trial implant will receive the permanent implant. At the 3-month end point, subjects in Arm 2 will be given the option to crossover into Arm 1 beginning with a trial implant. All Arm 1 patients receiving a permanent implant will be followed for a total of 36 months after permanent implantation. Arm 2 patients who do not crossover will be followed for a total of 36 months from randomization.

Tipo de estudio

Intervencionista

Inscripción (Actual)

131

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85258
        • Arizona Pain Specialists
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University of Arkansas Interventional Spine and Pain Clinic
    • California
      • Burbank, California, Estados Unidos, 91505
        • Comprehensive Spine & Pain Physicians
      • Redwood City, California, Estados Unidos, 94063
        • Stanford University Pain Management Center
      • Thousand Oaks, California, Estados Unidos, 91320
        • Pain Management and Injury Relief
    • Colorado
      • Denver, Colorado, Estados Unidos, 80111
        • DBPS Research LLC
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20006
        • International Spine, Pain & Performance Center
    • North Carolina
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • The Center for Clinical Research
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97401
        • Pacific Sports and Spine
      • Milwaukie, Oregon, Estados Unidos, 97222
        • Columbia Pain Management
    • Texas
      • Austin, Texas, Estados Unidos, 78745
        • Pain Specialists of America
      • Corpus Christi, Texas, Estados Unidos, 78414
        • Institute of Precision Pain Medicine
    • Washington
      • Spokane, Washington, Estados Unidos, 99216
        • Anesis Spine and Pain Care

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Subject is between 18 to 80 years of age at the time of enrollment.
  2. Subject would have been prescribed PNS therapy regardless of participation in this study; the use of the Nalu device must be on-label.
  3. Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle):Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment; Mononeuropathy, specified or unspecified or in diseases classified elsewhere; Other neuralgia or neuropathic pain; Osteoarthritic pain.
  4. Subject has chronic (defined as at least 6 months duration), intractable peripheral neuropathic pain, exclusive of the craniofacial region; any nociceptive pain must be less prominent than the neuropathic pain. Pain should have a predominant neuropathic component as per the investigator's clinical assessment.
  5. Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening.
  6. Subject is willing to cooperate with the study requirements including, compliance with the study procedures and completion of all study visits.
  7. Subject reported stable pain (non-escalating) for 60 days prior to signing informed consent.
  8. Subject is currently receiving CMM and has had stable pain medication use and dosage for 30 days prior to signing informed consent.
  9. Subject is psychologically qualified to receive a peripheral nerve stimulator as per the clinician's standard clinical practice and judgment and does not have clinically relevant psychological condition(s) that would interfere with their ability to accurately report outcomes or complete study procedures.
  10. Subject has demonstrated the ability to appropriately place the adhesive clip in the location where the IPG is most likely to be implanted. Alternatively, subject is able to appropriately use the relief belt and/or limb cuff to keep the Therapy Disc in place.

Exclusion Criteria:

  1. Subject currently has an active implantable medical device such as a drug pump, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, deep brain stimulator, and/or cardiac pacemaker.
  2. Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant)
  3. Pain is completely absent at rest.
  4. Patient has clinical evidence of complex regional pain syndrome (CRPS), peripheral neuralgia of metabolic origin, post-herpetic neuralgia, biochemical evidence of a metabolic or genetic neuropathy (e.g., Charcot'- Marie- Tooth Disease) or mixed motor/sensory polyneuropathy.
  5. Subject has a medical condition that would prevent them from participating in the current study per investigator's or medical monitor's judgment.
  6. Subject has had a successful (≥ 50% pain relief) interventional procedure within the past 3 months to treat the same pain condition(s) being examined in this study including, nerve blocks.
  7. Uncontrolled depression or uncontrolled psychiatric disorders
  8. Subject is currently participating in another clinical investigation with an active treatment arm.
  9. Subject is allergic or sensitive to materials used in the device components including, skin adhesives or does not tolerate the wearable aspect of the device.
  10. Subject has pending or ongoing legal issues (including unresolved worker's compensation claims or equivalent) or other conflicting secondary gain issues related to their chronic pain condition.
  11. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease that has not been medically corrected.
  12. Subject has an active systemic infection.
  13. Subject is unable to read and/or write in English or give informed consent.
  14. Subject has a life expectancy of less than 1 year.
  15. Subject has an active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome.
  16. Subject with uncontrolled diabetes mellitus, showing signs of diabetic neuropathy, as evidenced by a neurological exam and a HbA1c test.
  17. Subject has evidence of an alcohol or drug dependency within the last 6 months prior to enrollment.
  18. Subject is pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 1 year post-menopausal).
  19. Subject is nursing/breastfeeding.
  20. Subject is on ≥90 mg-morphine equivalents per 24 hours.
  21. Subject has undergone an ablative treatment of the target peripheral nerve, or proximal nerve trunk giving rise to the target nerve, or dorsal roots (and DRGs) that ultimately make up the target nerve. No ablative procedures directed at the spinal cord, dorsal roots, or peripheral nerve(s) being treated in the study. To note, subjects who have undergone RF ablation of the dorsal rami, cool pulsed RF of the facet innervation may be considered for enrollment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: PNS Therapy plus Conventional Medical Management

peripheral nerve stimulator plus conventional medical management

The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator

Otros nombres:
  • Nalu SNP

Conventional medical management

Otro: Conventional Medical Management

Control arm conventional medical management only

Conventional medical management

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Effectiveness: Responder Rates Between Groups
Periodo de tiempo: 3-months

Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).

3-months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Functional Outcomes: Change in Oswestry Disability Index (ODI) Score From Baseline to 3-month
Periodo de tiempo: 3 months

Change in patient reported ODI from baseline with comparison between groups. The ODI is a patient reported questionnaire used to measure functional disability and daily living impact. The ODI consists of ten topics, each scored from 0-5- pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life (optional), social life and traveling. The total score is used to calculate the percentage of disability from 0-100% and categorized as minimal, moderate, severe disability, crippled and bed bound. A lower score, compared to baseline, indicates improvement in ODI.

3 months
Functional Outcomes: Change in Beck's Depression Inventory (BDI) Score From Baseline
Periodo de tiempo: 3-months

Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up compared to baseline, indicates an improvement in depression symptoms and mood.

3-months
Functional Outcomes: Brief Pain Inventory (BPI; Interference)
Periodo de tiempo: 3-months

Brief Pain Inventory is a validated questionnaire to measure pain severity and how pain interferes with daily functioning.

Pain Interference (general activity, mood, walking, work, relationships, sleep, enjoyment of life; 0-10 scale where, 0=Does not interfere and 10= completely interferes)

3-months
Functional Outcomes: Brief Pain Inventory (BPI; Severity)
Periodo de tiempo: 3-months

Brief Pain Inventory is a validated questionnaire to measure pain severity using a 0-10 rating scale where, 0= no pain and 10= pain as bad as you can imagine.

3-months
Functional Outcomes: Quality of Life Using the EQ-5D-5L
Periodo de tiempo: 3-months

The EQ-5D-5L is a standardized, self-reported questionnaire used to measure health related quality of life across 5 dimension i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels from no problems to extreme problems. This produces a 5-digit code which is converted to an index value based on the health of the general population where a higher score indicates better health (0-1).

3-months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Patrick Martin, Nalu Medical

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

23 de febrero de 2022

Finalización primaria (Actual)

11 de diciembre de 2023

Finalización del estudio (Estimado)

11 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

8 de febrero de 2022

Primero enviado que cumplió con los criterios de control de calidad

10 de marzo de 2022

Publicado por primera vez (Actual)

18 de marzo de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir